A clinical trial study to evaluate the dermatological safety by primary irritation patch test
- Registration Number
- CTRI/2021/10/037327
- Lead Sponsor
- Maxwell Pharma SDN BHD
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 24
Females of childbearing potential must have a negative urine pregnancy test performed on Day 01 prior to patch application
Subjects who have sensitive skin determined by the Dermatologist on basis of skin sensitivity questionnaires during screening visit.
Subjects with positive reaction to lactic acid stinging test
Subjects who do not have any previous history of adverse skin conditions and are not under any medication.
Subject with good general health as determined by the Investigator on the basis of medical history.
Subjects willing to maintain the test patches in designated position for 24 hours.
Subjects willing to give a voluntary written informed consent.
Female subject is pregnant, planning for pergnancy or lactating.
Subjects having skin irritation, blemishes, excessive hair, moles, pigmentation, pimple marks, open wounds, sunburn, scars, tattoos, cuts, irritation symptoms.
Medication which may affect skin response and/or past medical history.
Subjects having history of diabetes.
Subject suffering from any active clinically significant skin diseases which may contraindicate.
Subjects having history of any skin diseases including eczema, atopic dermatitis or active cancer.
Subjects having history of asthma or COPD (Chronic obstructivepulmonary disease).
Subject with known allergy or sensitization to medical adhesives, bandages.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in Skin Condition will be evaluated for scoring after 30 �± 5 minutes of patch removal, 24�±2 hours of patch removal and 168�±2 hours after the patch removal. <br/ ><br>Changes in Skin Irritation will be evaluated for scoring by asking well-being of subject after 30 �± 5minutes of patch removal, 24�±2 hours of patch removaland 168�±2 hours after the patch removal.Timepoint: 30 �± 5 minutes of patch removal <br/ ><br>24�±2 hours of patch removal and <br/ ><br>168�±2 hours after the patch removal. <br/ ><br>
- Secondary Outcome Measures
Name Time Method To assess the safety of the subject by asking well-being of subject and Adverse event assessmentTimepoint: Day 01, 02, 03, 09.